Cell and gene therapy regulatory, pricing, and reimbursement framework: With a focus on South Korea and the EU
SK Lee, JH Lee - Frontiers in Public Health, 2023 - frontiersin.org
Ever since relevant bioengineering technologies have sufficiently matured to the
platformizable commercialization stage, a slew of money has flocked to the cell and gene …
platformizable commercialization stage, a slew of money has flocked to the cell and gene …
The value of flexible vaccine manufacturing capacity: value drivers, estimation methods, and approaches to value recognition in health technology assessment
Expanding flexible vaccine manufacturing capacity (FVMC) for routine vaccines could
facilitate more timely access to novel vaccines during future pandemics. Vaccine …
facilitate more timely access to novel vaccines during future pandemics. Vaccine …
Is NICE losing its standing as a trusted source of guidance?
JA Michaels - bmj, 2023 - bmj.com
The National Institute for Health and Care Excellence (NICE) develops healthcare guidance
for the NHS, aiming to provide “the best care for patients, while ensuring value for the …
for the NHS, aiming to provide “the best care for patients, while ensuring value for the …
Severity as a moral qualifier of malady
The overarching aim of this article is to scrutinize how severity can work as a qualifier for the
moral impetus of malady. While there is agreement that malady is of negative value, there is …
moral impetus of malady. While there is agreement that malady is of negative value, there is …
The normative grounds for NICE decision-making: a narrative cross-disciplinary review of empirical studies
V Charlton - Health Economics, Policy and Law, 2022 - cambridge.org
The National Institute for Health and Care Excellence (NICE) is the UK's primary health care
priority-setter, responsible for advising the National Health Service on its adoption of health …
priority-setter, responsible for advising the National Health Service on its adoption of health …
Resource allocation in the Covid-19 health crisis: are Covid-19 preventive measures consistent with the Rule of Rescue?
JW März, S Holm, M Schlander - Medicine, Health Care and Philosophy, 2021 - Springer
The Covid-19 pandemic has led to a health crisis of a scale unprecedented in post-war
Europe. In response, a large amount of healthcare resources have been redirected to Covid …
Europe. In response, a large amount of healthcare resources have been redirected to Covid …
An empirical ethics study of the coherence of NICE technology appraisal policy and its implications for moral justification
V Charlton, M DiStefano - BMC Medical Ethics, 2024 - Springer
Background As the UK's main healthcare priority-setter, the National Institute for Health and
Care Excellence (NICE) has good reason to want to demonstrate that its decisions are …
Care Excellence (NICE) has good reason to want to demonstrate that its decisions are …
Decision making and policy formulation: the case of health care coverage
I Williams - Research Handbook on Health Care Policy, 2024 - elgaronline.com
Health care policy makers across the world face levels of demand for services that frequently
outstrip what they are willing or able to provide, therefore requiring them to find ways to stem …
outstrip what they are willing or able to provide, therefore requiring them to find ways to stem …
Revision of Ireland's cost-effectiveness threshold: new state-industry drug pricing deal should adequately reflect opportunity costs
JF O'Mahony - PharmacoEconomics-Open, 2021 - Springer
Ireland's cost-effectiveness threshold is currently€ 45,000 per quality-adjusted life-year
(QALY). It has previously been determined by periodic agreements between the State and a …
(QALY). It has previously been determined by periodic agreements between the State and a …
Ethics of access to newly approved expensive medical treatments: multi-stakeholder dialogues in a publicly funded healthcare system
CHC Bomhof, J Smids, S Sybesma… - Frontiers in …, 2024 - frontiersin.org
Background: Due to rising healthcare expenditures, countries with publicly funded
healthcare systems face challenges when providing newly approved expensive anti-cancer …
healthcare systems face challenges when providing newly approved expensive anti-cancer …